Article Information
History
- May 4, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Abhishek Bhatia1,†,
- Alexander J. Preiss2,†,
- Xuya Xiao3,
- M. Daniel Brannock2,
- G. Caleb Alexander3,
- Robert F. Chew2,
- Megan Fitzgerald4,
- Elaine Hill5,
- Elizabeth P. Kelly1,
- Hemalkumar B. Mehta3,
- Charisse Madlock-Brown6,
- Kenneth J. Wilkins7,8,
- Christopher G. Chute3,
- Melissa Haendel9,
- Richard Moffitt10,
- Emily R. Pfaff1,
- The N3C Consortium11
- 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 2RTI International, Durham, NC, USA
- 3School of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, MD, USA
- 4Patient-Led Research Collaborative, NY, USA
- 5University of Rochester, Department of Public Health Sciences and Department of Economics, Rochester, NY, USA
- 6University of Tennessee Health Science Center, Memphis, TN, USA
- 7National Institute of Diabetes & Digestive & Kidney Diseases, Office of the Director, National Institutes of Health, Bethesda, MD, USA
- 8F. Edward Hébert School of Medicine, Department of Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
- 9University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 10Stony Brook University, Stony Brook, NY, USA
- 11Consortial acknowledgements appear at the end of the paper
- Contributing authors: abhatia{at}unc.edu;
↵† These authors contributed equally to this work.
Posted May 04, 2023.
Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C
